BioSpace News Archive

HKG Epitherapeutics announced today that the International Journal of Cancer has published new data on the ability of the Company’s proprietary epiCervix test to detect cervical cancer in patients sooner compared to traditional screening methods, including manual laboratory cell examination from Papanicolaou (Pap) smears and human papillomavirus (HPV) testing.

UroAmp, the noninvasive genomic urine test developed by Convergent Genomics, can detect bladder cancer or predict its recurrence before clinical signs or symptoms appear, according to a newly published study in the journal Clinical Cancer Research.

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of September.

Longhorn Vaccines and Diagnostics LLC announced today new data validating the company’s core diagnostic product, PrimeStore® Molecular Transport Medium (MTM), and its potential to increase access to Mycobacterium tuberculosis (TB) testing for children in remote and underserved areas and reduce time to diagnosis and initiation of life-saving treatment.

Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated generic injectables company based in Chicago, today announced it has entered into a $35 million senior secured revolving credit agreement with J.P. Morgan.

Simcha Therapeutics today announced the formation of a scientific advisory board that will support the company’s efforts to realize the potential of IL-18-focused therapeutic approaches.

Halberd Corporation (OTC PINK:HALB) announced Mississippi State University (MSU) has finalized the collection of tissue samples from a quantity of the planned test subjects.

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced that the company will host an Investor Day on September 19, 2023, from 9:30 AM ET to 1:00 PM ET.

Twist Bioscience Corporation today released its environmental, social and governance (ESG) report for 2023, highlighting Twist’s approach to sustainability, social responsibility and commitment to ethics.

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer.